GlaxoSmithLine has announced that it has created an effective low-dose vaccine against the H5n1 strain of avian influenza. Clinical trials have yielded excellent results, Chief Executive Jean-Pierre Garnier said, predicting that production could begin later this year and hundreds of millions of doses could be available by 2007.
